For example, the integration of a truncated TGF-β receptor 2 (TGFBR2) to native or transgenic TCR T cells conferred resistance to TGF-β mediated immunosuppression, and enhanced proliferation, cytokine production and anti-tumor function in models of EBV-associated lymphoma, prostate carcinoma or melanoma [211,212,213,214,215,216]. The gene discussed is TGFBR2; the disease is prostate carcinoma.